{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T19:54:21Z","timestamp":1787860461896,"version":"build-2784847793"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,24]]},"DOI":"10.7759\/cureus.35402","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T12:21:58Z","timestamp":1677241318000},"source":"Crossref","is-referenced-by-count":1,"title":["Impact of SARS-CoV-2\/COVID-19 on Provision of Medical Care to Patients With Systemic Autoimmune Rheumatic Disease and the Practice of Rheumatology"],"prefix":"10.7759","author":[{"given":"Adegbenga A","family":"Bankole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Nwaonu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jahanzeb","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Coronavirus disease (COVID-19). Weekly Epidemiological Updates and Monthly Operational Updates. (2022). Accessed. September 2022: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2020.03.011","article-title":"Interrupting COVID-19 transmission by implementing enhanced traffic control bundling: implications for global prevention and control efforts","volume":"53","author":"Yen MY","year":"2020","unstructured":"Yen MY, Schwartz J, Chen SY, King CC, Yang GY, Hsueh PR. Interrupting COVID-19 transmission by implementing enhanced traffic control bundling: implications for global prevention and control efforts. J Microbiol Immunol Infect. 2020, 53:377-80. 10.1016\/j.jmii.2020.03.011","journal-title":"J Microbiol Immunol Infect"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2020.05.044","article-title":"COVID-19: transmission, prevention, and potential therapeutic opportunities","volume":"508","author":"Lotfi M","year":"2020","unstructured":"Lotfi M, Hamblin MR, Rezaei N. COVID-19: transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta. 2020, 508:254-66. 10.1016\/j.cca.2020.05.044","journal-title":"Clin Chim Acta"},{"key":"ref4","unstructured":"International travel to and from the United States. (2022). Accessed. September 2022: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/travelers\/international-travel-during-covid19.html."},{"key":"ref5","unstructured":"COVID data tracker. US Department of Health and Human Services, CDC. (2023). https.\/\/covid.cdc.gov\/covid-data-tracker\/."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1017\/dmp.2020.303","article-title":"Reduced emergency department utilization during the early phase of the COVID-19 pandemic: viral fear or lockdown effect?","volume":"16","author":"Barten DG","year":"2022","unstructured":"Barten DG, Latten GH, van Osch FH. Reduced emergency department utilization during the early phase of the COVID-19 pandemic: viral fear or lockdown effect?. Disaster Med Public Health Prep. 2022, 16:36-9. 10.1017\/dmp.2020.303","journal-title":"Disaster Med Public Health Prep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6936a4","article-title":"Delay or avoidance of medical care because of COVID-19-related concerns \u2014 United States, June 2020","volume":"69","author":"Czeisler M\u00c9","year":"2020","unstructured":"Czeisler M\u00c9, Marynak K, Clarke KE, et al.. Delay or avoidance of medical care because of COVID-19-related concerns \u2014 United States, June 2020. MMWR Morb Mortal Wkly Rep. 2020, 69:1250-7. 10.15585\/mmwr.mm6936a4","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb2021088","article-title":"Covid-19 \u2014 implications for the health care system","volume":"383","author":"Blumenthal D","year":"2020","unstructured":"Blumenthal D, Fowler EJ, Abrams M, Collins SR. Covid-19 \u2014 implications for the health care system. N Engl J Med. 2020, 383:1483-8. 10.1056\/NEJMsb2021088","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20953356","article-title":"Impact of COVID-19 outbreak in an Italian cohort of patients with systemic sclerosis","volume":"12","author":"Del Papa N","year":"2020","unstructured":"Del Papa N, Sambataro G, Minniti A, et al.. Impact of COVID-19 outbreak in an Italian cohort of patients with systemic sclerosis. Ther Adv Musculoskelet Dis. 2020, 12:1759720X20953356. 10.1177\/1759720X20953356","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000001448","article-title":"Effects of the COVID-19 pandemic on outpatient providers in the United States","volume":"59","author":"Chatterji P","year":"2021","unstructured":"Chatterji P, Li Y. Effects of the COVID-19 pandemic on outpatient providers in the United States. Med Care. 2021, 59:58-61. 10.1097\/MLR.0000000000001448","journal-title":"Med Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.5928","article-title":"Trends in outpatient care delivery and telemedicine during the COVID-19 pandemic in the US","volume":"181","author":"Patel SY","year":"2021","unstructured":"Patel SY, Mehrotra A, Huskamp HA, Uscher-Pines L, Ganguli I, Barnett ML. Trends in outpatient care delivery and telemedicine during the COVID-19 pandemic in the US. JAMA Intern Med. 2021, 181:388-91. 10.1001\/jamainternmed.2020.5928","journal-title":"JAMA Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1377\/forefront.20200715.454789","article-title":"Early impact of CMS expansion of Medicare telehealth during COVID-19","author":"Verma S","year":"2020","unstructured":"Verma S. Early impact of CMS expansion of Medicare telehealth during COVID-19. Health Affairs. 2020, 10.1377\/forefront.20200715.454789","journal-title":"Health Affairs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.03.008","article-title":"Telemedicine in the era of COVID-19","volume":"8","author":"Portnoy J","year":"2020","unstructured":"Portnoy J, Waller M, Elliott T. Telemedicine in the era of COVID-19. J Allergy Clin Immunol Pract. 2020, 8:1489-91. 10.1016\/j.jaip.2020.03.008","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001378","article-title":"Impact of COVID-19 on vulnerable patients with rheumatic disease: results of a worldwide survey","volume":"6","author":"Mehta B","year":"2020","unstructured":"Mehta B, Jannat-Khah D, Fontana MA, et al.. Impact of COVID-19 on vulnerable patients with rheumatic disease: results of a worldwide survey. RMD Open. 2020, 6:e001378. 10.1136\/rmdopen-2020-001378","journal-title":"RMD Open"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-020-09944-5","article-title":"The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections","volume":"15","author":"Machhi J","year":"2020","unstructured":"Machhi J, Herskovitz J, Senan AM, et al.. The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. J Neuroimmune Pharmacol. 2020, 15:359-86. 10.1007\/s11481-020-09944-5","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/01410768211032850","article-title":"Symptoms, complications and management of long COVID: a review","volume":"114","author":"Aiyegbusi OL","year":"2021","unstructured":"Aiyegbusi OL, Hughes SE, Turner G, et al.. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021, 114:428-42. 10.1177\/01410768211032850","journal-title":"J R Soc Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25509-3","article-title":"New-onset IgG autoantibodies in hospitalized patients with COVID-19","volume":"12","author":"Chang SE","year":"2021","unstructured":"Chang SE, Feng A, Meng W, et al.. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021, 12:5417. 10.1038\/s41467-021-25509-3","journal-title":"Nat Commun"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000776","article-title":"COVID-19 and autoimmune diseases","volume":"33","author":"Liu Y","year":"2021","unstructured":"Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021, 33:155-62. 10.1097\/BOR.0000000000000776","journal-title":"Curr Opin Rheumatol"},{"key":"ref19","article-title":"COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19. NICE Guideline, No. 188","author":"NICE","year":"2020","unstructured":"NICE. COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19. NICE Guideline, No. 188. National Institute for Health and Care Excellence, London; 2020."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-021-01130-1","article-title":"The neurological manifestations of post-acute sequelae of SARS-CoV-2 infection","volume":"21","author":"Moghimi N","year":"2021","unstructured":"Moghimi N, Di Napoli M, Biller J, et al.. The neurological manifestations of post-acute sequelae of SARS-CoV-2 infection. Curr Neurol Neurosci Rep. 2021, 21:44. 10.1007\/s11910-021-01130-1","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101019","article-title":"Characterizing long COVID in an international cohort: 7 months of symptoms and their impact","volume":"38","author":"Davis HE","year":"2021","unstructured":"Davis HE, Assaf GS, McCorkell L, et al.. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. eClinicalMedicine. 2021, 38:101019. 10.1016\/j.eclinm.2021.101019","journal-title":"eClinicalMedicine"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080\/10852352.2014.973239","article-title":"Problems in defining post-exertional malaise","volume":"43","author":"Jason LA","year":"2015","unstructured":"Jason LA, Evans M, So S, Scott J, Brown A. Problems in defining post-exertional malaise. J Prev Interv Community. 2015, 43:20-31. 10.1080\/10852352.2014.973239","journal-title":"J Prev Interv Community"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57050418","article-title":"Long COVID and myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS)\u2014a systemic review and comparison of clinical presentation and symptomatology","volume":"57","author":"Wong TL","year":"2021","unstructured":"Wong TL, Weitzer DJ. Long COVID and myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS)\u2014a systemic review and comparison of clinical presentation and symptomatology. Medicina (Kaunas). 2021, 57:418. 10.3390\/medicina57050418","journal-title":"Medicina (Kaunas)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05942-x","article-title":"Long COVID: rheumatologic\/musculoskeletal symptoms in hospitalized COVID-19 survivors at 3 and 6\u00a0months","volume":"41","author":"Karaarslan F","year":"2022","unstructured":"Karaarslan F, G\u00fcneri FD, Karde\u015f S. Long COVID: rheumatologic\/musculoskeletal symptoms in hospitalized COVID-19 survivors at 3 and 6\u00a0months. Clin Rheumatol. 2022, 41:289-96. 10.1007\/s10067-021-05942-x","journal-title":"Clin Rheumatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-013-0407-3","article-title":"Complexities in the relationship between infection and autoimmunity","volume":"14","author":"Root-Bernstein R","year":"2014","unstructured":"Root-Bernstein R, Fairweather D. Complexities in the relationship between infection and autoimmunity. Curr Allergy Asthma Rep. 2014, 14:407. 10.1007\/s11882-013-0407-3","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102597","article-title":"Covid-19 and autoimmunity","volume":"19","author":"Ehrenfeld M","year":"2020","unstructured":"Ehrenfeld M, Tincani A, Andreoli L, et al.. Covid-19 and autoimmunity. Autoimmun Rev. 2020, 19:102597. 10.1016\/j.autrev.2020.102597","journal-title":"Autoimmun Rev"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154886","article-title":"The intersection of COVID-19 and autoimmunity","volume":"131","author":"Knight JS","year":"2021","unstructured":"Knight JS, Caricchio R, Casanova JL, et al.. The intersection of COVID-19 and autoimmunity. J Clin Invest. 2021, 131:e154886. 10.1172\/JCI154886","journal-title":"J Clin Invest"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.6","article-title":"Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE","volume":"10","author":"Deane KD","year":"2014","unstructured":"Deane KD, El-Gabalawy H. Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE. Nat Rev Rheumatol. 2014, 10:212-28. 10.1038\/nrrheum.2014.6","journal-title":"Nat Rev Rheumatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16104","article-title":"A flare of systemic lupus erythematosus disease after COVID-19 infection: a case of lupus cerebritis","volume":"13","author":"Khalid MZ","year":"2021","unstructured":"Khalid MZ, Rogers S, Fatima A, Dawe M, Singh R. A flare of systemic lupus erythematosus disease after COVID-19 infection: a case of lupus cerebritis. Cureus. 2021, 13:e16104. 10.7759\/cureus.16104","journal-title":"Cureus"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102883","article-title":"Rheumatological complications of Covid 19","volume":"20","author":"Zacharias H","year":"2021","unstructured":"Zacharias H, Dubey S, Koduri G, D'Cruz D. Rheumatological complications of Covid 19. Autoimmun Rev. 2021, 20:102883. 10.1016\/j.autrev.2021.102883","journal-title":"Autoimmun Rev"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12908","article-title":"COVID-19 and immunological dysregulation: can autoantibodies be useful?","volume":"14","author":"Pascolini S","year":"2021","unstructured":"Pascolini S, Vannini A, Deleonardi G, et al.. COVID-19 and immunological dysregulation: can autoantibodies be useful?. Clin Transl Sci. 2021, 14:502-8. 10.1111\/cts.12908","journal-title":"Clin Transl Sci"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-15969-y","article-title":"Anti-cardiolipin IgG autoantibodies associate with circulating extracellular DNA in severe COVID-19","volume":"12","author":"Bertin D","year":"2022","unstructured":"Bertin D, Brodovitch A, Lopez A, et al.. Anti-cardiolipin IgG autoantibodies associate with circulating extracellular DNA in severe COVID-19. Sci Rep. 2022, 12:12523. 10.1038\/s41598-022-15969-y","journal-title":"Sci Rep"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12805","article-title":"Clinical and autoimmune characteristics of severe and critical cases of COVID-19","volume":"13","author":"Zhou Y","year":"2020","unstructured":"Zhou Y, Han T, Chen J, et al.. Clinical and autoimmune characteristics of severe and critical cases of COVID-19. Clin Transl Sci. 2020, 13:1077-86. 10.1111\/cts.12805","journal-title":"Clin Transl Sci"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/cells10123592","article-title":"New onset of autoimmune diseases following COVID-19 diagnosis","volume":"10","author":"Gracia-Ramos AE","year":"2021","unstructured":"Gracia-Ramos AE, Martin-Nares E, Hern\u00e1ndez-Molina G. New onset of autoimmune diseases following COVID-19 diagnosis. Cells. 2021, 10:3592. 10.3390\/cells10123592","journal-title":"Cells"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218100","article-title":"Presence of antiphospholipid antibodies in COVID-19: a case series study","volume":"80","author":"Amezcua-Guerra LM","year":"2021","unstructured":"Amezcua-Guerra LM, Rojas-Velasco G, Brianza-Padilla M, et al.. Presence of antiphospholipid antibodies in COVID-19: a case series study. Ann Rheum Dis. 2021, 80:e73. 10.1136\/annrheumdis-2020-218100","journal-title":"Ann Rheum Dis"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13623","article-title":"Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2\u00a0infection","volume":"205","author":"Richter AG","year":"2021","unstructured":"Richter AG, Shields AM, Karim A, et al.. Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2\u00a0infection. Clin Exp Immunol. 2021, 205:99-105. 10.1111\/cei.13623","journal-title":"Clin Exp Immunol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl4340","article-title":"Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths","volume":"6","author":"Bastard P","year":"2021","unstructured":"Bastard P, Gervais A, Le Voyer T, et al.. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021, 6:10.1126\/sciimmunol.abl4340","journal-title":"Sci Immunol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05180-7","article-title":"High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia","volume":"39","author":"Gazzaruso C","year":"2020","unstructured":"Gazzaruso C, Carlo Stella N, Mariani G, Nai C, Coppola A, Naldani D, Gallotti P. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia. Clin Rheumatol. 2020, 39:2095-7. 10.1007\/s10067-020-05180-7","journal-title":"Clin Rheumatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102682","article-title":"Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals","volume":"122","author":"Lingel H","year":"2021","unstructured":"Lingel H, Meltendorf S, Billing U, et al.. Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals. J Autoimmun. 2021, 122:102682. 10.1016\/j.jaut.2021.102682","journal-title":"J Autoimmun"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006695","article-title":"Red cell-bound antibodies and transfusion requirements in hospitalized patients with COVID-19","volume":"136","author":"Berzuini A","year":"2020","unstructured":"Berzuini A, Bianco C, Paccapelo C, et al.. Red cell-bound antibodies and transfusion requirements in hospitalized patients with COVID-19. Blood. 2020, 136:766-8. 10.1182\/blood.2020006695","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12953","article-title":"SARS-CoV-2 infection as a trigger of autoimmune response","volume":"14","author":"Sacchi MC","year":"2021","unstructured":"Sacchi MC, Tamiazzo S, Stobbione P, et al.. SARS-CoV-2 infection as a trigger of autoimmune response. Clin Transl Sci. 2021, 14:898-907. 10.1111\/cts.12953","journal-title":"Clin Transl Sci"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-021-00671-1","article-title":"Antineutrophil cytoplasmic antibodies and their association with clinical outcomes in hospitalized COVID-19 patients","volume":"7","author":"Kadkhoda K","year":"2021","unstructured":"Kadkhoda K, Laurita K. Antineutrophil cytoplasmic antibodies and their association with clinical outcomes in hospitalized COVID-19 patients. Cell Death Discov. 2021, 7:277. 10.1038\/s41420-021-00671-1","journal-title":"Cell Death Discov"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-020-00146-3","article-title":"How COVID-19 induces cytokine storm with high mortality","volume":"40","author":"Hojyo S","year":"2020","unstructured":"Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M, Hirano T. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020, 40:37. 10.1186\/s41232-020-00146-3","journal-title":"Inflamm Regen"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31129-6","article-title":"Kawasaki-like disease: emerging complication during the COVID-19 pandemic","volume":"395","author":"Viner RM","year":"2020","unstructured":"Viner RM, Whittaker E. Kawasaki-like disease: emerging complication during the COVID-19 pandemic. Lancet. 2020, 395:1741-3. 10.1016\/S0140-6736(20)31129-6","journal-title":"Lancet"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2007575","article-title":"Coagulopathy and antiphospholipid antibodies in patients with Covid-19","volume":"382","author":"Zhang Y","year":"2020","unstructured":"Zhang Y, Xiao M, Zhang S, et al.. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020, 382:e38. 10.1056\/NEJMc2007575","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23153","article-title":"Telerheumatology: a systematic review","volume":"69","author":"McDougall JA","year":"2017","unstructured":"McDougall JA, Ferucci ED, Glover J, Fraenkel L. Telerheumatology: a systematic review. Arthritis Care Res (Hoboken). 2017, 69:1546-57. 10.1002\/acr.23153","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph182413127","article-title":"Opportunities and barriers of telemedicine in rheumatology: a participatory, mixed-methods study","volume":"18","author":"Muehlensiepen F","year":"2021","unstructured":"Muehlensiepen F, Knitza J, Marquardt W, et al.. Opportunities and barriers of telemedicine in rheumatology: a participatory, mixed-methods study. Int J Environ Res Public Health. 2021, 18:13127. 10.3390\/ijerph182413127","journal-title":"Int J Environ Res Public Health"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s11420-020-09810-3","article-title":"Telemedicine in rheumatology at the advent of the COVID-19 pandemic","volume":"16","author":"Gkrouzman E","year":"2020","unstructured":"Gkrouzman E, Wu DD, Jethwa H, Abraham S. Telemedicine in rheumatology at the advent of the COVID-19 pandemic. HSS J. 2020, 16:108-11. 10.1007\/s11420-020-09810-3","journal-title":"HSS J"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1089\/tmj.2020.0570","article-title":"A review of patient satisfaction and experience with telemedicine: a virtual solution during and beyond COVID-19 pandemic","volume":"27","author":"Nanda M","year":"2021","unstructured":"Nanda M, Sharma R. A review of patient satisfaction and experience with telemedicine: a virtual solution during and beyond COVID-19 pandemic. Telemed J E Health. 2021, 27:1325-31. 10.1089\/tmj.2020.0570","journal-title":"Telemed J E Health"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa554","article-title":"Telemedicine in rheumatology: a reliable approach beyond the pandemic","volume":"60","author":"Cavagna L","year":"2021","unstructured":"Cavagna L, Zanframundo G, Codullo V, Pisu MG, Caporali R, Montecucco C. Telemedicine in rheumatology: a reliable approach beyond the pandemic. Rheumatology (Oxford). 2021, 60:366-70. 10.1093\/rheumatology\/keaa554","journal-title":"Rheumatology (Oxford)"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1177\/23743735211008825","article-title":"Rheumatology patient satisfaction with telemedicine during the COVID-19 pandemic in the United States","volume":"8","author":"Mortezavi M","year":"2021","unstructured":"Mortezavi M, Lokineni S, Garg M, Chen YL, Ramsey A. Rheumatology patient satisfaction with telemedicine during the COVID-19 pandemic in the United States. J Patient Exp. 2021, 8:23743735211008825. 10.1177\/23743735211008825","journal-title":"J Patient Exp"},{"key":"ref52","unstructured":"COVID-19. Understanding risk. Information for specific groups. (2022). Accessed: September 2022: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/index.html."},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.09.009","article-title":"Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission","volume":"58","author":"van Gerven NM","year":"2013","unstructured":"van Gerven NM, Verwer BJ, Witte BI, et al.. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol. 2013, 58:141-7. 10.1016\/j.jhep.2012.09.009","journal-title":"J Hepatol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"79","author":"Gianfrancesco M","year":"2020","unstructured":"Gianfrancesco M, Hyrich KL, Al-Adely S, et al.. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020, 79:859-66. 10.1136\/annrheumdis-2020-217871","journal-title":"Ann Rheum Dis"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1111\/imj.15142","article-title":"Immunosuppression as a risk factor for COVID-19: a meta-analysis","volume":"51","author":"Tassone D","year":"2021","unstructured":"Tassone D, Thompson A, Connell W, et al.. Immunosuppression as a risk factor for COVID-19: a meta-analysis. Intern Med J. 2021, 51:199-205. 10.1111\/imj.15142","journal-title":"Intern Med J"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30169-7","article-title":"COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study","volume":"2","author":"Fredi M","year":"2020","unstructured":"Fredi M, Cavazzana I, Moschetti L, Andreoli L, Franceschini F. COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study. Lancet Rheumatol. 2020, 2:e549-56. 10.1016\/S2665-9913(20)30169-7","journal-title":"Lancet Rheumatol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.20950","article-title":"The shifting landscape of lupus nephritis management: a review","volume":"14","author":"Bankole AA","year":"2022","unstructured":"Bankole AA, Nwaonu JN. The shifting landscape of lupus nephritis management: a review. Cureus. 2022, 14:e20950. 10.7759\/cureus.20950","journal-title":"Cureus"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001461","article-title":"High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry","volume":"7","author":"Marques CD","year":"2021","unstructured":"Marques CD, Kakehasi AM, Pinheiro MM, et al.. High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry. RMD Open. 2021, 7:e001461. 10.1136\/rmdopen-2020-001461","journal-title":"RMD Open"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102139","article-title":"Rethinking high-risk groups in COVID-19","volume":"42","author":"Vishnevetsky A","year":"2020","unstructured":"Vishnevetsky A, Levy M. Rethinking high-risk groups in COVID-19. Mult Scler Relat Disord. 2020, 42:102139. 10.1016\/j.msard.2020.102139","journal-title":"Mult Scler Relat Disord"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.07.089","article-title":"Antecedent immunosuppressive therapy for immune-mediated inflammatory diseases in the setting of a COVID-19 outbreak","volume":"83","author":"Veenstra J","year":"2020","unstructured":"Veenstra J, Buechler CR, Robinson G, et al.. Antecedent immunosuppressive therapy for immune-mediated inflammatory diseases in the setting of a COVID-19 outbreak. J Am Acad Dermatol. 2020, 83:1696-703. 10.1016\/j.jaad.2020.07.089","journal-title":"J Am Acad Dermatol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05779-4","article-title":"Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs","volume":"40","author":"Yousefghahari B","year":"2021","unstructured":"Yousefghahari B, Navari S, Sadeghi M, et al.. Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs. Clin Rheumatol. 2021, 40:4309-15. 10.1007\/s10067-021-05779-4","journal-title":"Clin Rheumatol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11148","article-title":"Experiences of patients with rheumatic diseases in the United States during early days of the COVID-19 pandemic","volume":"2","author":"Michaud K","year":"2020","unstructured":"Michaud K, Wipfler K, Shaw Y, et al.. Experiences of patients with rheumatic diseases in the United States during early days of the COVID-19 pandemic. ACR Open Rheumatol. 2020, 2:335-43. 10.1002\/acr2.11148","journal-title":"ACR Open Rheumatol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102502","article-title":"SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: a cross-sectional study on 916 patients","volume":"112","author":"Zen M","year":"2020","unstructured":"Zen M, Fuzzi E, Astorri D, et al.. SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: a cross-sectional study on 916 patients. J Autoimmun. 2020, 112:102502. 10.1016\/j.jaut.2020.102502","journal-title":"J Autoimmun"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.31.3.247","article-title":"The rheumatologist's role in the battle against COVID-19: insights from the front line and challenges for the future","volume":"31","author":"Koutsianas C","year":"2020","unstructured":"Koutsianas C, Chatzidionysiou K. The rheumatologist's role in the battle against COVID-19: insights from the front line and challenges for the future. Mediterr J Rheumatol. 2020, 31:247-52. 10.31138\/mjr.31.3.247","journal-title":"Mediterr J Rheumatol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"Li G","year":"2020","unstructured":"Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020, 19:149-50. 10.1038\/d41573-020-00016-0","journal-title":"Nat Rev Drug Discov"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-022-00642-4","article-title":"Therapeutic advances in COVID-19","volume":"19","author":"Murakami N","year":"2023","unstructured":"Murakami N, Hayden R, Hills T, et al.. Therapeutic advances in COVID-19. Nat Rev Nephrol. 2023, 19:38-52. 10.1038\/s41581-022-00642-4","journal-title":"Nat Rev Nephrol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent MJ","year":"2005","unstructured":"Vincent MJ, Bergeron E, Benjannet S, et al.. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005, 2:69. 10.1186\/1743-422X-2-69","journal-title":"Virol J"},{"key":"ref68","article-title":"Chloroquine and hydroxychloroquine toxicity","author":"Stokkermans TJ","year":"2022","unstructured":"Stokkermans TJ, Goyal A, Trichonas G. Chloroquine and hydroxychloroquine toxicity. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2022."},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for Covid-19 \u2014 interim WHO Solidarity Trial results","volume":"384","author":"Pan H","year":"2021","unstructured":"Pan H, Peto R, Henao-Restrepo AM, et al.. Repurposed antiviral drugs for Covid-19 \u2014 interim WHO Solidarity Trial results. N Engl J Med. 2021, 384:497-511. 10.1056\/NEJMoa2023184","journal-title":"N Engl J Med"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa403","article-title":"Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis","volume":"76","author":"Kashour Z","year":"2021","unstructured":"Kashour Z, Riaz M, Garbati MA, et al.. Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis. J Antimicrob Chemother. 2021, 76:30-42. 10.1093\/jac\/dkaa403","journal-title":"J Antimicrob Chemother"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01648","article-title":"Cytokine storm in COVID-19-immunopathological mechanisms, clinical considerations, and therapeutic approaches: the REPROGRAM Consortium position paper","volume":"11","author":"Bhaskar S","year":"2020","unstructured":"Bhaskar S, Sinha A, Banach M, et al.. Cytokine storm in COVID-19-immunopathological mechanisms, clinical considerations, and therapeutic approaches: the REPROGRAM Consortium position paper. Front Immunol. 2020, 11:1648. 10.3389\/fimmu.2020.01648","journal-title":"Front Immunol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-021-01449-2","article-title":"The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical trial (ESCoRT study)","volume":"21","author":"Zhao J","year":"2021","unstructured":"Zhao J, Zhou W, Wu Y, Ji P, Yang L, Yan X, Zhang Z. The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical trial (ESCoRT study). BMC Med Inform Decis Mak. 2021, 21:83. 10.1186\/s12911-021-01449-2","journal-title":"BMC Med Inform Decis Mak"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00899-z","article-title":"Circulating levels of interleukin-6 and interleukin-10, but not tumor necrosis factor-alpha, as potential biomarkers of severity and mortality for COVID-19: systematic review with meta-analysis","volume":"41","author":"Udomsinprasert W","year":"2021","unstructured":"Udomsinprasert W, Jittikoon J, Sangroongruangsri S, Chaikledkaew U. Circulating levels of interleukin-6 and interleukin-10, but not tumor necrosis factor-alpha, as potential biomarkers of severity and mortality for COVID-19: systematic review with meta-analysis. J Clin Immunol. 2021, 41:11-22. 10.1007\/s10875-020-00899-z","journal-title":"J Clin Immunol"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.613422","article-title":"Interleukin-6 is a biomarker for the development of fatal severe acute respiratory syndrome coronavirus 2 pneumonia","volume":"12","author":"Santa Cruz A","year":"2021","unstructured":"Santa Cruz A, Mendes-Frias A, Oliveira AI, et al.. Interleukin-6 is a biomarker for the development of fatal severe acute respiratory syndrome coronavirus 2 pneumonia. Front Immunol. 2021, 12:613422. 10.3389\/fimmu.2021.613422","journal-title":"Front Immunol"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26085","article-title":"Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis","volume":"93","author":"Zhu J","year":"2021","unstructured":"Zhu J, Pang J, Ji P, Zhong Z, Li H, Li B, Zhang J. Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis. J Med Virol. 2021, 93:35-7. 10.1002\/jmv.26085","journal-title":"J Med Virol"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with Covid-19 pneumonia","volume":"384","author":"Salama C","year":"2021","unstructured":"Salama C, Han J, Yau L, et al.. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021, 384:20-30. 10.1056\/NEJMoa2030340","journal-title":"N Engl J Med"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu X","year":"2020","unstructured":"Xu X, Han M, Li T, et al.. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020, 117:10970-5. 10.1073\/pnas.2005615117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.3390\/geriatrics7010022","article-title":"Efficacy of single tocilizumab administration in an 88-year-old patient with severe COVID-19 and a mini literature review","volume":"7","author":"Ould Ouali C","year":"2022","unstructured":"Ould Ouali C, Ladjouzi N, Tamas K, et al.. Efficacy of single tocilizumab administration in an 88-year-old patient with severe COVID-19 and a mini literature review. Geriatrics (Basel). 2022, 7:22. 10.3390\/geriatrics7010022","journal-title":"Geriatrics (Basel)"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe Covid-19 pneumonia","volume":"384","author":"Rosas IO","year":"2021","unstructured":"Rosas IO, Br\u00e4u N, Waters M, et al.. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021, 384:1503-16. 10.1056\/NEJMoa2028700","journal-title":"N Engl J Med"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190314","article-title":"Inflammasome signaling and regulation of interleukin-1 family cytokines","volume":"217","author":"Chan AH","year":"2020","unstructured":"Chan AH, Schroder K. Inflammasome signaling and regulation of interleukin-1 family cytokines. J Exp Med. 2020, 217:e20190314. 10.1084\/jem.20190314","journal-title":"J Exp Med"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.08.011","article-title":"Inhibition of interleukin-1\u03b2 and reduction in atherothrombotic cardiovascular events in the CANTOS trial","volume":"76","author":"Everett BM","year":"2020","unstructured":"Everett BM, MacFadyen JG, Thuren T, Libby P, Glynn RJ, Ridker PM. Inhibition of interleukin-1\u03b2 and reduction in atherothrombotic cardiovascular events in the CANTOS trial. J Am Coll Cardiol. 2020, 76:1660-70. 10.1016\/j.jacc.2020.08.011","journal-title":"J Am Coll Cardiol"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-03166-0","article-title":"Blocking IL-1 to prevent respiratory failure in COVID-19","volume":"24","author":"van de Veerdonk FL","year":"2020","unstructured":"van de Veerdonk FL, Netea MG. Blocking IL-1 to prevent respiratory failure in COVID-19. Crit Care. 2020, 24:445. 10.1186\/s13054-020-03166-0","journal-title":"Crit Care"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.9.5395","article-title":"Cross-talk between IL-1 and IL-6 signaling pathways in rheumatoid arthritis synovial fibroblasts","volume":"167","author":"Deon D","year":"2001","unstructured":"Deon D, Ahmed S, Tai K, et al.. Cross-talk between IL-1 and IL-6 signaling pathways in rheumatoid arthritis synovial fibroblasts. J Immunol. 2001, 167:5395-403. 10.4049\/jimmunol.167.9.5395","journal-title":"J Immunol"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.815","article-title":"Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review","volume":"301","author":"Annane D","year":"2009","unstructured":"Annane D, Bellissant E, Bollaert PE, et al.. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA. 2009, 301:2362-75. 10.1001\/jama.2009.815","journal-title":"JAMA"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02518-2021","article-title":"Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial","volume":"60","author":"Taboada M","year":"2022","unstructured":"Taboada M, Rodr\u00edguez N, Varela PM, et al.. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. Eur Respir J. 2022, 60:2102518. 10.1183\/13993003.02518-2021","journal-title":"Eur Respir J"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17023","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis","volume":"324","author":"Sterne JA","year":"2020","unstructured":"Sterne JA, Murthy S, Diaz JV, et al.. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020, 324:1330-41. 10.1001\/jama.2020.17023","journal-title":"JAMA"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101362","article-title":"Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: a randomised clinical trial from the CORIMUNO-19 study group","volume":"46","author":"Hermine O","year":"2022","unstructured":"Hermine O, Mariette X, Porcher R, et al.. Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: a randomised clinical trial from the CORIMUNO-19 study group. eClinicalMedicine. 2022, 46:101362. 10.1016\/j.eclinm.2022.101362","journal-title":"eClinicalMedicine"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu X","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021, 6:402. 10.1038\/s41392-021-00791-1","journal-title":"Signal Transduct Target Ther"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0891-0","article-title":"The Janus kinase 1\/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation","volume":"34","author":"La Ros\u00e9e F","year":"2020","unstructured":"La Ros\u00e9e F, Bremer HC, Gehrke I, et al.. The Janus kinase 1\/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia. 2020, 34:1805-15. 10.1038\/s41375-020-0891-0","journal-title":"Leukemia"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1159\/000508247","article-title":"JAK inhibition as a new treatment strategy for patients with COVID-19","volume":"181","author":"Seif F","year":"2020","unstructured":"Seif F, Aazami H, Khoshmirsafa M, Kamali M, Mohsenzadegan M, Pornour M, Mansouri D. JAK inhibition as a new treatment strategy for patients with COVID-19. Int Arch Allergy Immunol. 2020, 181:467-75. 10.1159\/000508247","journal-title":"Int Arch Allergy Immunol"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214846","article-title":"Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials","volume":"78","author":"Xie W","year":"2019","unstructured":"Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2019, 78:1048-54. 10.1136\/annrheumdis-2018-214846","journal-title":"Ann Rheum Dis"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00325-8","article-title":"Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative","volume":"4","author":"Andersen KM","year":"2022","unstructured":"Andersen KM, Bates BA, Rashidi ES, et al.. Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative. Lancet Rheumatol. 2022, 4:e33-41. 10.1016\/S2665-9913(21)00325-8","journal-title":"Lancet Rheumatol"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218075","article-title":"Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab","volume":"80","author":"Schulze-Koops H","year":"2021","unstructured":"Schulze-Koops H, Krueger K, Vallbracht I, Hasseli R, Skapenko A. Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann Rheum Dis. 2021, 80:e67. 10.1136\/annrheumdis-2020-218075","journal-title":"Ann Rheum Dis"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1002\/art.42058","article-title":"Rituximab impairs B cell response but not T cell response to COVID-19 vaccine in autoimmune diseases","volume":"74","author":"Bitoun S","year":"2022","unstructured":"Bitoun S, Henry J, Desjardins D, et al.. Rituximab impairs B cell response but not T cell response to COVID-19 vaccine in autoimmune diseases. Arthritis Rheumatol. 2022, 74:927-33. 10.1002\/art.42058","journal-title":"Arthritis Rheumatol"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-021-01046-2","article-title":"The use of COVID-19 vaccines in patients with SLE","volume":"23","author":"Tang W","year":"2021","unstructured":"Tang W, Gartshteyn Y, Ricker E, Inzerillo S, Murray S, Khalili L, Askanase A. The use of COVID-19 vaccines in patients with SLE. Curr Rheumatol Rep. 2021, 23:79. 10.1007\/s11926-021-01046-2","journal-title":"Curr Rheumatol Rep"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(22)00096-0","article-title":"Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis","volume":"4","author":"Widdifield J","year":"2022","unstructured":"Widdifield J, Kwong JC, Chen S, et al.. Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis. Lancet Rheumatol. 2022, 4:e430-40. 10.1016\/S2665-9913(22)00096-0","journal-title":"Lancet Rheumatol"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(22)00034-0","article-title":"Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study","volume":"4","author":"Wieske L","year":"2022","unstructured":"Wieske L, van Dam KP, Steenhuis M, et al.. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatol. 2022, 4:e338-50. 10.1016\/S2665-9913(22)00034-0","journal-title":"Lancet Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/138797-impact-of-sars-cov-2covid-19-on-provision-of-medical-care-to-patients-with-systemic-autoimmune-rheumatic-disease-and-the-practice-of-rheumatology","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:51:16Z","timestamp":1707508276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/138797-impact-of-sars-cov-2covid-19-on-provision-of-medical-care-to-patients-with-systemic-autoimmune-rheumatic-disease-and-the-practice-of-rheumatology"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,24]]},"references-count":97,"URL":"https:\/\/doi.org\/10.7759\/cureus.35402","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,24]]}}}